Theravance
Top Ten most popular articles on Pharmafile.com this week
February 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Allergan, Antibiotics, Avycaz, Elastagen, FDA, GSK, India, J&J, JJ, Nektar Therapeutics, Novartis, Theravance, artificial intelligence, pharma
It’s top ten time again. This week, among our most popular stories was the worrying news that, accoridng to research …
GSK sees FDA clearance for asthma drug
May 1, 2015Sales and Marketing Breo Ellipta, FDA, GSK, Theravance
GlaxoSmithKline and Theravance’s Breo Ellipta inhaler has been approved by the FDA to treat asthma in adults. Whilst the once-daily treatment …
GSK and Theravance see FDA nod for asthma indication
March 20, 2015Sales and Marketing Advair, AstraZeneca, Dulera, FDA, Foradil, GSK, Merck, Symbicort, Theravance, asthma, breo, budesonide/formoterol fumarate dihydratem, ellipta, fluticasone propionate, formoterol fumarate, mometasone/formoterol
An FDA panel has recommended the approval of asthma treatment Breo Ellipta in adults – but voted against supporting its …
Second late-stage COPD trial for GSK and Theravance
February 10, 2015Sales and Marketing COPD, FF/UMEC/VI, GSK, Theravance, fluticasone furoate, umeclidinium, vilanterol
GlaxoSmithKline and Theravance have begun a second Phase III trial of their investigational triple combination COPD drug as the former …
GSK/Theravance lung drug bags CHMP approval
February 21, 2014Sales and Marketing CHMP, COPD, GSK, Theravance, anoro
The CHMP has given its backing to GlaxoSmithKline and partner Theravance’s new chronic obstructive pulmonary disease medicine Anoro. The treatment …
Elan signs $1 billion finance deal with Theravance
May 15, 2013Research and Development, Sales and Marketing Elan, Theravance, royalty pharma
Elan has struck a novel deal with Theravance which gives it a share of potential future royalties from its respiratory …
FDA accepts GSK’s Anoro
February 20, 2013Research and Development, Sales and Marketing FDA, GSK, Theravance, anoro
The FDA has accepted a New Drug Application for GlaxoSmithKline and biopharma firm Theravance’s investigational COPD drug UMEC/VI. A decision …
EU submission for GSK and Theravance COPD drug
January 11, 2013Sales and Marketing COPD, GSK, Theravance, UMEC/VI
GlaxoSmithKline and Theravance have submitted their chronic obstructive pulmonary disease (COPD) drug UMEC/VI to European regulators. The application follows the …
Merck signs Theravance cardio deal
October 19, 2012Sales and Marketing Merck, Theravance, cardiovascular
Merck has signed a deal with US biopharma firm Theravance to discover and develop novel small molecules to treat cardiovascular …
GSK and Theravance file COPD drug
July 16, 2012Research and Development, Sales and Marketing EMA, GSK, Relovair, Revlar, Spiriva, Theravance
GlaxoSmithKline and US biopharma firm Theravance have submitted their investigational chronic obstructive pulmonary disease (COPD) drug to regulators in Europe …
GSK and Theravance post COPD pill data
July 2, 2012Research and Development, Sales and Marketing COPD, GSK, LABA, LAMA, Theravance
GSK and partner Theravance have released new data for its combination COPD drug. Results from four late-stage trials suggest that …
GSK buys more of Theravance
May 18, 2012Research and Development, Sales and Marketing COPD, Cellzome, GSK, Relovair, Theravance
GlaxoSmithKline now owns more than a quarter of biopharma company Theravance after shelling out nearly $213 million to buy ten …
GSK’s Relovair moves into phase III
March 19, 2010Research and Development GlaxoSmithKline, Relovair, Seretide, Theravance, respiratory
GlaxoSmithKline has started phase III asthma trials of Relovair, the respiratory treatment it is developing with San Francisco biopharma firm …
GSK begins phase III COPD trials
October 28, 2009Research and Development, Sales and Marketing COPD, GSK, GlaxoSmithKline, Seretide, Theravance, resp, respiratory
GlaxoSmithKline and San Francisco biopharma firm Theravance have begun a phase III trial to develop a new treatment for chronic …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
